EGFR and lung adenocarcinoma: Treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors is more effective for patients with EGFR-mutated lung adenocarcinoma and acceptable for EGFR-mutated NSCLC with brain metastases [8].